Skip to content

Source Profiling of Biohazardous Aerosols in Hospitals

Source Profiling of Biohazardous Aerosols in Hospitals

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00517660
Enrollment
60
Registered
2007-08-17
Start date
2006-03-31
Completion date
2006-06-30
Last updated
2013-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Tract Infections

Keywords

Healthy subjects, Lower Respiratory Tract Infections, Upper Respiratory Tract Infections

Brief summary

To characterise the physical parameters (number concentration, size distribution and their trajectories) of aerosols (droplets) generated in high risk procedures.

Interventions

None listed

Sponsors

Hong Kong University of Science and Technology
CollaboratorOTHER
Hospital Authority, Hong Kong
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Adult patients (\>18 years old) that can give valid consent 2. URTI: with symptoms such as coryza, sore throat, nasal discharge, cough and sputum +/- fever. Amongst these, cough should be a major complaint. 3. LRTI (CAP): acute lower respiratory illness of no other known cause which is usually associated with fever, symptoms and signs of the chest and abnormalities on the CXR. (BTS 1993).

Exclusion criteria

1. Pneumonia developed at or after 48 hours, or history of hospital admissions within 1 month of the present admission (to exclude hospital-acquired infections) 2. Patients who are unable to cooperate with the study protocols (such as mentally confused, dementia) or are physically unable to sit or stand independently to carry out the tests optimally. 3. Patients with TOCC associations with infections such Avian Flu or SARS (travel to endemic areas, at-risk occupations, close contacts with index cases, especially with compatible clinical features) or NPA revealed positivity of influenza A/B 4. Patients who are clinically or haemodynamically unstable, such as the need for inotropes, oxygen supplement of \>2L/min, any types of shock, etc. 5. Underlying diseases that might affect the coughing effort (such as musculoskeletal diseases, or severe kyphoscoliosis)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026